-
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines
Daivd Orchard Webb/PharmaSources
July 03, 2023
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
-
First study to show waning effectiveness of 3rd dose of mRNA vaccines
WorldPharmaNews
February 14, 2022
A nationwide study from the U.S. Centers for Disease Control and Prevention (CDC) is the first to show that immunity against severe COVID-19 disease begins to wane 4 months after receipt of the third dose of an mRNA vaccine (Pfizer or Moderna).
-
Johnson & Johnson's Covid-19 vaccine holds up in US durability study
FirstWordPharma
January 07, 2022
Findings were unveiled Thursday from the largest US study to date on the durability of COVID-19 vaccines, with Johnson & Johnson's jab producing a robust result in terms...
-
Tonix and Kansas State University to develop mRNA vaccines for Covid-19
Pharmaceutical-Technology
January 06, 2022
The ZNP technology could offer increased stability to mRNA vaccines at various temperatures.
-
Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response
WorldPharmaNews
December 02, 2021
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada...
-
Biotage expands production capacity to ease lipid bottlenecks
cphi-online
August 19, 2021
New site in Cardiff boosts the company's production capacity for equipment crucial in the supply chain for mRNA vaccines production
-
Investigation of reports of myocarditis in connection with COVID-19 mRNA vaccines
firstwordpharma
June 07, 2021
Very rare reports received worldwide of myocarditis with a possible link to the use of mRNA vaccines against COVID-19 are currently under investigation.
-
Precision NanoSystems joins Danaher's Life Sciences Platform
firstwordpharma
June 02, 2021
Precision NanoSystems (PNI) has been acquired by Danaher Corporation's Life Sciences platform. PNI is a global leader in technologies and solutions for the development of genetic medicines, including mRNA vaccines and therapeutics.
-
Merck KGaA boosts lipid capacity to meet vaccine demand
cphi-online
May 31, 2021
The company's new synthetic cholesterol product will help meet the demand for mRNA vaccines, including Pfizer-BioNTech Covid-19 Vaccine
-
Global Trial for COVID-19 Vaccine Begins at NYU Langone Health
americanpharmaceuticalreview
August 04, 2020
The first U.S. patients are being dosed in a Phase 2/3 clinical trial testing whether a messenger RNA (mRNA) vaccine candidate can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).